Avapritinib-d3

Avapritinib-d3 (BLU-285-d3) is deuterium labeled Avapritinib. Avapritinib (BLU-285) is a highly potent, selective, and orally active KIT and PDGFRA activation loop mutant kinases inhibitor with IC50s of 0.27 and 0.24 nM for KIT D816V and PDGFRA D842V, respectively. Avapritinib (BLU-285) binds the active conformation of the kinase and shows antitumor activity. Avapritinib (BLU-285) attenuates the transport function of both ABCB1 and ABCG2[1][2].

Product Specifications

CAS Number

[2408934-57-4]

Product Name Alternative

BLU-285-d3

UNSPSC

12352005

Target

C-Kit; Isotope-Labeled Compounds; PDGFR

Related Pathways

Others; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

C[C@](N)(C1=CC=C(C=C1)F)C2=CN=C(N=C2)N(CC3)CCN3C4=NC=NN5C4=CC(C(C=N6)=CN6C([2H])([2H])[2H])=C5

Molecular Formula

C26H24D3FN10

Molecular Weight

501.58

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Wu CP, et al. Avapritinib: A Selective Inhibitor of KIT and PDGFRα that Reverses ABCB1 and ABCG2-MediatedMultidrug Resistance in Cancer Cell Lines. Mol Pharm. 2019 Jul 1;16 (7) :3040-3052.|[3]Evans EK, et al. A precision therapy against cancers driven by KIT/PDGFRA mutations. Sci Transl Med. 2017 Nov 1;9 (414) . pii: eaao1690.|[4]Erica Evans, et al. Blu-285, a Potent and Selective Inhibitor for Hematologic Malignancies with KIT Exon 17 Mutations.Blood 2015 126:568.